Report cover image

Global Psoriasis Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 197 Pages
SKU # APRC20277160

Description

Summary

According to APO Research, The global Psoriasis Biosimilar market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Psoriasis Biosimilar include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Psoriasis Biosimilar, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Psoriasis Biosimilar, also provides the revenue of main regions and countries. Of the upcoming market potential for Psoriasis Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Psoriasis Biosimilar revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Psoriasis Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Psoriasis Biosimilar revenue, projected growth trends, production technology, application and end-user industry.

Psoriasis Biosimilar Segment by Company

Amgen Inc
Celltrion
Coherus BioSciences
Fresenius Kabi
GenScript
Gyros Protein Technologies AB
Hoffmann-La Roche Ltd
Novartis International AG
Reddy's Laboratories
Samsung Bioepis
Samsung Bioepis Co., Ltd.
Viatris
Pfizer Inc.
Merck KGaA
Sandoz
Psoriasis Biosimilar Segment by Type

TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Other Biosimilars
Psoriasis Biosimilar Segment by Application

Plaque Psoriasis
Psoriatic Arthritis
Other
Psoriasis Biosimilar Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Psoriasis Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psoriasis Biosimilar industry.
Chapter 3: Detailed analysis of Psoriasis Biosimilar companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psoriasis Biosimilarrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Psoriasis Biosimilar Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
1.2.3 Other Biosimilars
1.3 Market Analysis by Application
1.3.1 Global Psoriasis Biosimilar Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Plaque Psoriasis
1.3.3 Psoriatic Arthritis
1.3.4 Other
1.4 Global Market Growth Prospects
1.5 Global Psoriasis Biosimilar Growth Trends by Region
1.5.1 Global Psoriasis Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Psoriasis Biosimilar Market Size by Region (2020-2025)
1.5.3 Psoriasis Biosimilar Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Psoriasis Biosimilar Market Dynamics
2.1 Psoriasis Biosimilar Industry Trends
2.2 Psoriasis Biosimilar Industry Drivers
2.3 Psoriasis Biosimilar Industry Opportunities and Challenges
2.4 Psoriasis Biosimilar Industry Restraints
3 Competitive Landscape by Company
3.1 Global Psoriasis Biosimilar Revenue by Company (2020-2025)
3.2 Global Psoriasis Biosimilar Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Psoriasis Biosimilar Key Company Head office and Area Served
3.4 Global Psoriasis Biosimilar Company, Product Type & Application
3.5 Global Psoriasis Biosimilar Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Psoriasis Biosimilar Market CR5 and HHI
3.6.2 Global Top 5 and 10 Psoriasis Biosimilar Players Market Share by Revenue in 2024
3.6.3 2024 Psoriasis Biosimilar Tier 1, Tier 2, and Tier 3
4 Psoriasis Biosimilar Market by Type
4.1 Global Psoriasis Biosimilar Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Psoriasis Biosimilar Market Size by Type (2020-2031)
4.3 Global Psoriasis Biosimilar Market Size Share by Type (2020-2031)
5 Psoriasis Biosimilar Market by Application
5.1 Global Psoriasis Biosimilar Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Psoriasis Biosimilar Market Size by Application (2020-2031)
5.3 Global Psoriasis Biosimilar Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Amgen Inc
6.1.1 Amgen Inc Comapny Information
6.1.2 Amgen Inc Business Overview
6.1.3 Amgen Inc Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
6.1.5 Amgen Inc Recent Developments
6.2 Celltrion
6.2.1 Celltrion Comapny Information
6.2.2 Celltrion Business Overview
6.2.3 Celltrion Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
6.2.5 Celltrion Recent Developments
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Comapny Information
6.3.2 Coherus BioSciences Business Overview
6.3.3 Coherus BioSciences Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
6.3.5 Coherus BioSciences Recent Developments
6.4 Fresenius Kabi
6.4.1 Fresenius Kabi Comapny Information
6.4.2 Fresenius Kabi Business Overview
6.4.3 Fresenius Kabi Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
6.4.5 Fresenius Kabi Recent Developments
6.5 GenScript
6.5.1 GenScript Comapny Information
6.5.2 GenScript Business Overview
6.5.3 GenScript Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 GenScript Psoriasis Biosimilar Product Portfolio
6.5.5 GenScript Recent Developments
6.6 Gyros Protein Technologies AB
6.6.1 Gyros Protein Technologies AB Comapny Information
6.6.2 Gyros Protein Technologies AB Business Overview
6.6.3 Gyros Protein Technologies AB Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
6.6.5 Gyros Protein Technologies AB Recent Developments
6.7 Hoffmann-La Roche Ltd
6.7.1 Hoffmann-La Roche Ltd Comapny Information
6.7.2 Hoffmann-La Roche Ltd Business Overview
6.7.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
6.7.5 Hoffmann-La Roche Ltd Recent Developments
6.8 Novartis International AG
6.8.1 Novartis International AG Comapny Information
6.8.2 Novartis International AG Business Overview
6.8.3 Novartis International AG Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
6.8.5 Novartis International AG Recent Developments
6.9 Reddy's Laboratories
6.9.1 Reddy's Laboratories Comapny Information
6.9.2 Reddy's Laboratories Business Overview
6.9.3 Reddy's Laboratories Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
6.9.5 Reddy's Laboratories Recent Developments
6.10 Samsung Bioepis
6.10.1 Samsung Bioepis Comapny Information
6.10.2 Samsung Bioepis Business Overview
6.10.3 Samsung Bioepis Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
6.10.5 Samsung Bioepis Recent Developments
6.11 Samsung Bioepis Co., Ltd.
6.11.1 Samsung Bioepis Co., Ltd. Comapny Information
6.11.2 Samsung Bioepis Co., Ltd. Business Overview
6.11.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
6.11.5 Samsung Bioepis Co., Ltd. Recent Developments
6.12 Viatris
6.12.1 Viatris Comapny Information
6.12.2 Viatris Business Overview
6.12.3 Viatris Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.12.4 Viatris Psoriasis Biosimilar Product Portfolio
6.12.5 Viatris Recent Developments
6.13 Pfizer Inc.
6.13.1 Pfizer Inc. Comapny Information
6.13.2 Pfizer Inc. Business Overview
6.13.3 Pfizer Inc. Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
6.13.5 Pfizer Inc. Recent Developments
6.14 Merck KGaA
6.14.1 Merck KGaA Comapny Information
6.14.2 Merck KGaA Business Overview
6.14.3 Merck KGaA Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
6.14.5 Merck KGaA Recent Developments
6.15 Sandoz
6.15.1 Sandoz Comapny Information
6.15.2 Sandoz Business Overview
6.15.3 Sandoz Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2020-2025)
6.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
6.15.5 Sandoz Recent Developments
7 North America
7.1 North America Psoriasis Biosimilar Market Size (2020-2031)
7.2 North America Psoriasis Biosimilar Market Size by Type
7.2.1 North America Psoriasis Biosimilar Market Size by Type (2020-2025)
7.2.2 North America Psoriasis Biosimilar Market Size by Type (2026-2031)
7.2.3 North America Psoriasis Biosimilar Market Share by Type (2020-2031)
7.3 North America Psoriasis Biosimilar Market Size by Application
7.3.1 North America Psoriasis Biosimilar Market Size by Application (2020-2025)
7.3.2 North America Psoriasis Biosimilar Market Size by Application (2026-2031)
7.3.3 North America Psoriasis Biosimilar Market Share by Application (2020-2031)
7.4 North America Psoriasis Biosimilar Market Size by Country
7.4.1 North America Psoriasis Biosimilar Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Psoriasis Biosimilar Market Size by Country (2020-2025)
7.4.3 North America Psoriasis Biosimilar Market Size by Country (2026-2031)
7.4.4 North America Psoriasis Biosimilar Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Psoriasis Biosimilar Market Size (2020-2031)
8.2 Europe Psoriasis Biosimilar Market Size by Type
8.2.1 Europe Psoriasis Biosimilar Market Size by Type (2020-2025)
8.2.2 Europe Psoriasis Biosimilar Market Size by Type (2026-2031)
8.2.3 Europe Psoriasis Biosimilar Market Share by Type (2020-2031)
8.3 Europe Psoriasis Biosimilar Market Size by Application
8.3.1 Europe Psoriasis Biosimilar Market Size by Application (2020-2025)
8.3.2 Europe Psoriasis Biosimilar Market Size by Application (2026-2031)
8.3.3 Europe Psoriasis Biosimilar Market Share by Application (2020-2031)
8.4 Europe Psoriasis Biosimilar Market Size by Country
8.4.1 Europe Psoriasis Biosimilar Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Psoriasis Biosimilar Market Size by Country (2020-2025)
8.4.3 Europe Psoriasis Biosimilar Market Size by Country (2026-2031)
8.4.4 Europe Psoriasis Biosimilar Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Psoriasis Biosimilar Market Size (2020-2031)
9.2 China Psoriasis Biosimilar Market Size by Type
9.2.1 China Psoriasis Biosimilar Market Size by Type (2020-2025)
9.2.2 China Psoriasis Biosimilar Market Size by Type (2026-2031)
9.2.3 China Psoriasis Biosimilar Market Share by Type (2020-2031)
9.3 China Psoriasis Biosimilar Market Size by Application
9.3.1 China Psoriasis Biosimilar Market Size by Application (2020-2025)
9.3.2 China Psoriasis Biosimilar Market Size by Application (2026-2031)
9.3.3 China Psoriasis Biosimilar Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Psoriasis Biosimilar Market Size (2020-2031)
10.2 Asia Psoriasis Biosimilar Market Size by Type
10.2.1 Asia Psoriasis Biosimilar Market Size by Type (2020-2025)
10.2.2 Asia Psoriasis Biosimilar Market Size by Type (2026-2031)
10.2.3 Asia Psoriasis Biosimilar Market Share by Type (2020-2031)
10.3 Asia Psoriasis Biosimilar Market Size by Application
10.3.1 Asia Psoriasis Biosimilar Market Size by Application (2020-2025)
10.3.2 Asia Psoriasis Biosimilar Market Size by Application (2026-2031)
10.3.3 Asia Psoriasis Biosimilar Market Share by Application (2020-2031)
10.4 Asia Psoriasis Biosimilar Market Size by Country
10.4.1 Asia Psoriasis Biosimilar Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Psoriasis Biosimilar Market Size by Country (2020-2025)
10.4.3 Asia Psoriasis Biosimilar Market Size by Country (2026-2031)
10.4.4 Asia Psoriasis Biosimilar Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size (2020-2031)
11.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Type
11.2.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Psoriasis Biosimilar Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Application
11.3.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Psoriasis Biosimilar Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country
11.4.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Psoriasis Biosimilar Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.